Interferon Regulatory Factor 5
IRF5 is a master transcription factor controlling innate and adaptive immune responses via TLR7/9 and other pattern recognition pathways. It drives pro-inflammatory cytokine production (TNFα, IL-6, IL-12, IL-23), type I interferon signaling, and B-cell differentiation toward plasma cells. Human genetics firmly links IRF5 to lupus (SLE) and other autoimmune diseases. No approved IRF5-targeted therapy exists — it has never been drugged.
IRF5 exists in an inactive cytoplasmic conformation maintained by auto-inhibitory interactions between its DBD and IAD2 domains. Activation requires: (1) TLR7/9 or MyD88-dependent signaling triggers K63-ubiquitination and IRAK1/TRAF6-mediated phosphorylation; (2) IRF5 dimerizes; (3) nuclear translocation drives type I IFN gene expression (IFN-α/β), pro-inflammatory cytokines (TNFα, IL-6, IL-12, IL-23), and chemokines. In B-cells, IRF5 additionally drives plasma cell differentiation and antibody class switching. The multiple activation steps and lack of a canonical ATP-binding domain have made IRF5 historically undruggable.
IRF5 has no traditional small-molecule binding pocket — no kinase domain, no deep hydrophobic groove accessible with drug-like molecules. The DBD (DNA-binding domain) is shallow; the IAD2 dimerization interface is large and flat. PROTAC degradation is uniquely suited: the degrader molecule doesn't need to inhibit function, only bind with sufficient affinity for ternary complex formation with an E3 ligase. KT-579 is the first IRF5-targeted molecule to reach human trials.
No therapeutic agents targeting IRF5 have reached the clinic in any modality. Attempted approaches in research settings include: DBD-targeting small molecules (failed due to shallow surface), IAD2 inhibitors (low affinity, poor cellular activity), antisense oligonucleotides (delivery challenges). KT-579 represents the first human clinical attempt at IRF5 targeting.
pChEMBL = −log₁₀(IC₅₀). Higher value = more potent. Dashed line = 100 nM threshold. Showing top binding compounds in ChEMBL (74 total activities).
Potentially the first IRF5-targeted therapy ever to enter human trials. IRF5 is a strong genetic risk factor for lupus and multiple other autoimmune diseases per GWAS studies. No approved or investigational IRF5-targeted therapy exists in any modality. KT-579 is wholly owned by Kymera.
Preclinical data only; Phase 1 HV study planned Q1 2026. First-in-human readout expected H2 2026.
No other company has a targeted protein degrader program against IRF5 in the clinic. Kymera holds first-mover advantage in this target.
Primary disease activity composite for SLE trials. Responder threshold: SLEDAI reduction ≥4 from baseline.
Composite SLE response measure used in Phase 2/3 trials including anifrolumab (Saphnelo).
Composite measure requiring SLEDAI-2K ≥4 reduction plus no worsening in BILAG or physician assessment.
Pharmacodynamic biomarker measuring IFIT1, IFIT2, IFIT3, IFI27 expression in whole blood. Used to stratify patients and measure target engagement.
Primary endpoint for Sjögren's trials, covering 12 organ domains.
Total patient potential: Tens of millions globally across lupus, Sjögren's, RA, systemic sclerosis, and related autoimmune diseases